Futura Medical (FUM) Competitors

30.7% of Synairgen shares are owned by institutional investors. Comparatively, 1.0% of Futura Medical shares are owned by institutional investors. 3.2% of Synairgen shares are owned by insiders. Comparatively, 16.0% of Futura Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Futura Medical had 2 more articles in the media than Synairgen. MarketBeat recorded 2 mentions for Futura Medical and 0 mentions for Synairgen. Futura Medical's average media sentiment score of 0.60 beat Synairgen's score of 0.00 indicating that Futura Medical is being referred to more favorably in the news media.

Futura Medical has higher revenue and earnings than Synairgen. Futura Medical is trading at a lower price-to-earnings ratio than Synairgen, indicating that it is currently the more affordable of the two stocks.

Synairgen has a beta of -2.23, meaning that its stock price is 323% less volatile than the broader market. Comparatively, Futura Medical has a beta of 0.021, meaning that its stock price is 98% less volatile than the broader market.

Synairgen has a net margin of 0.00% compared to Futura Medical's net margin of -534.62%. Synairgen's return on equity of -51.06% beat Futura Medical's return on equity.

BiVictriX Therapeutics has a net margin of 0.00% compared to Futura Medical's net margin of -534.62%. BiVictriX Therapeutics' return on equity of -103.99% beat Futura Medical's return on equity.

1.0% of Futura Medical shares are held by institutional investors. Comparatively, 30.8% of BiVictriX Therapeutics shares are held by institutional investors. 16.0% of Futura Medical shares are held by insiders. Comparatively, 42.6% of BiVictriX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BiVictriX Therapeutics has lower revenue, but higher earnings than Futura Medical. Futura Medical is trading at a lower price-to-earnings ratio than BiVictriX Therapeutics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Futura Medical had 2 more articles in the media than BiVictriX Therapeutics. MarketBeat recorded 2 mentions for Futura Medical and 0 mentions for BiVictriX Therapeutics. Futura Medical's average media sentiment score of 0.60 beat BiVictriX Therapeutics' score of 0.00 indicating that Futura Medical is being referred to more favorably in the media.

Futura Medical has a beta of 0.021, meaning that its share price is 98% less volatile than the broader market. Comparatively, BiVictriX Therapeutics has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market.

25.4% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 1.0% of Futura Medical shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 16.0% of Futura Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Oxford BioDynamics and Oxford BioDynamics both had 2 articles in the media. Futura Medical's average media sentiment score of 0.60 beat Oxford BioDynamics' score of -0.16 indicating that Futura Medical is being referred to more favorably in the news media.

Futura Medical has higher revenue and earnings than Oxford BioDynamics. Futura Medical is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

Futura Medical has a net margin of -534.62% compared to Oxford BioDynamics' net margin of -1,018.54%. Futura Medical's return on equity of -310.00% beat Oxford BioDynamics' return on equity.

Oxford BioDynamics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Futura Medical has a beta of 0.021, meaning that its stock price is 98% less volatile than the broader market.

0.4% of OptiBiotix Health shares are owned by institutional investors. Comparatively, 1.0% of Futura Medical shares are owned by institutional investors. 26.8% of OptiBiotix Health shares are owned by insiders. Comparatively, 16.0% of Futura Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

OptiBiotix Health has a net margin of -333.62% compared to Futura Medical's net margin of -534.62%. OptiBiotix Health's return on equity of -52.92% beat Futura Medical's return on equity.

OptiBiotix Health has higher earnings, but lower revenue than Futura Medical. OptiBiotix Health is trading at a lower price-to-earnings ratio than Futura Medical, indicating that it is currently the more affordable of the two stocks.

OptiBiotix Health has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, Futura Medical has a beta of 0.021, suggesting that its stock price is 98% less volatile than the broader market.

In the previous week, Futura Medical had 2 more articles in the media than OptiBiotix Health. MarketBeat recorded 2 mentions for Futura Medical and 0 mentions for OptiBiotix Health. Futura Medical's average media sentiment score of 0.60 beat OptiBiotix Health's score of 0.00 indicating that Futura Medical is being referred to more favorably in the news media.